argenx SE

ARGX: XBRU (BEL)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|s$LOCK|z@^LOCK|$r%pJSD

Argenx Earnings: Demand for Vyvgart Fuels Growth by Supporting Developing Pipeline

Argenx reported $949 million in second-quarter net product sales, with Vyvgart reaching over 15,000 patients globally across generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Sponsor Center